Alzheimer s Research & Therapy, Journal Year: 2024, Volume and Issue: 16(1)
Published: Sept. 12, 2024
Language: Английский
Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 96, P. 102290 - 102290
Published: April 1, 2024
Language: Английский
Citations
12
Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15
Published: April 9, 2024
Background Plasma biomarkers are preferable to invasive and expensive diagnostic tools, such as neuroimaging lumbar puncture that gold standard in the clinical management of Alzheimer’s Disease (AD). Here, we investigated plasma Glial Fibrillary Acidic Protein (GFAP), Neurofilament Light Chain (NfL) Phosphorylated-tau-181 (pTau 181) AD its early stages: Subjective cognitive decline (SCD) Mild impairment (MCI). Material methods This study included 152 patients (42 SCD, 74 MCI 36 AD). All underwent comprehensive neurological assessment. Blood samples were collected for Apolipoprotein E (APOE) genotyping biomarker (GFAP, NfL, pTau measurements. Forty-three (7 27 MCI, 9 AD) a follow-up (FU) visit after 2 years, second sample was collected. levels detected using Simoa SR-X technology (Quanterix Corp.). Statistical analysis performed SPSS software version 28 (IBM Statistics). significance set at p < 0.05. Results GFAP, NfL 181 lower SCD than patients. In particular, GFAP statistically significant different between ( =0.003), =0.032). vs =0.026), <0.001), FU p=0.033 ), p=0.011 =0.002), =0.003) =0.003). concentration significantly =0.001), =0.020). APOE ϵ4 carriers, increase p<0.001 ) found p=0.014). Moreover, an association emerged age disease onset (p = 0.021) pTau181 0.001) levels. Discussion conclusions promising diagnosis prodromic stages prognosis dementia.
Language: Английский
Citations
8
Neurochemical Research, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 30, 2024
Language: Английский
Citations
5
European Journal of Neurology, Journal Year: 2023, Volume and Issue: 31(1)
Published: Oct. 5, 2023
We aimed to evaluate the accuracy of plasma neurofilament light chain (NfL) in predicting Alzheimer's disease (AD) and progression cognitive decline patients with subjective (SCD) mild impairment (MCI).
Language: Английский
Citations
11
Frontiers in Neuroscience, Journal Year: 2025, Volume and Issue: 19
Published: Feb. 13, 2025
Purpose Subjective cognitive decline (SCD) is an early manifestation of the Alzheimer’s disease (AD) continuum, and accurately diagnosing SCD to differentiate it from neurotypical aging in older adults a common challenge for researchers. Methods This review examines summarizes relevant studies regarding neuroimaging AD comprehensively outlines clinical features characterizing along with corresponding changes involving structural, functional, metabolic networks. Results The characteristics include subjective self-perceived function, there are significant imaging changes, such as reductions gray matter volume certain brain regions, abnormalities integrity white tracts diffusion metrics, alterations functional connectivity between different sub-networks or within networks, well networks cerebral blood flow perfusion. Conclusion 147 referenced this paper indicate that exploring network related through aims enhance goals mission science development programs: “Understanding Brain,” “Protecting “Creating thereby strengthening researchers’ investigation into mechanisms function. Early diagnosis SCD, prompt intervention, can reduce incidence spectrum while improving patients’ quality life, even integrating numerous scientific research achievements unified established standards applying them practice by doctors, thus all encouraging researchers further investigate issues adults.
Language: Английский
Citations
0
NeuroImage Clinical, Journal Year: 2025, Volume and Issue: 45, P. 103760 - 103760
Published: Jan. 1, 2025
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7808 - 7808
Published: July 17, 2024
Multiple studies have shown the importance of blood-based biomarkers indicating axonal damage (serum neurofilament light chains [sNfL]) or astroglia activation glial fibrillary acidic protein [sGFAP]) for monitoring different neurological diseases. However, normal values these variables remain to be clearly defined, partly due influence demographic factors. We investigated differences in a cohort healthy volunteers. A cross-sectional study was conducted including 116 controls with ages between 18 and 69 years (67.5% females; n = 79). sNfL sGFAP concentrations were measured using single-molecule arrays. Age body mass index affected values, age found most important factor. The changed age, we established individuals younger than 45 as <10 pg/mL older <15 pg/mL. at individuals. Alternatively, Z-score 1.5 relevant all controls. only by age. Differences evident 55 years. highest normality limit 140 under 280 defined levels their corresponding age-associated changes. These data may contribute application such clinical practice.
Language: Английский
Citations
3
Neurological Sciences, Journal Year: 2023, Volume and Issue: 45(3), P. 1031 - 1039
Published: Sept. 19, 2023
Abstract Introduction and aim NfL GFAP are promising blood-based biomarkers for Alzheimer's disease. However, few studies have explored plasma in the prodromal preclinical stages of AD. In our cross-sectional study, is to investigate role these earliest Materials methods We enrolled 40 patients (11 SCD, 21 MCI, 8 AD dementia). All underwent neurological neuropsychological examinations, analysis CSF (Aβ 42 , Aβ /Aβ p-tau, t-tau), Apolipoprotein E ( APOE ) genotype measurement concentrations. Patients were categorized according ATN system as follows: normal (NB), carriers non-Alzheimer's pathology (non-AD), AD, or with dementia (AD-D). Results was lower NB compared p = 0.003, d 1.463) AD-D 0.002, 1.695). than 0.011, 1.474). demonstrated fair accuracy (AUC 0.718) differentiating between a cut-off value 11.65 pg/mL. showed excellent from 0.901) level 198.13 Conclusions exhibited distinguishing those Our results support use this peripheral biomarker detecting subjective objective cognitive decline.
Language: Английский
Citations
7
Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)
Published: May 17, 2024
Abstract We aimed to assess diagnostic accuracy of plasma p-tau181 and NfL separately in combination discriminating Subjective Cognitive Decline (SCD) Mild Impairment (MCI) patients carrying Alzheimer’s Disease (AD) pathology from non-carriers; propose a flowchart for the interpretation results NfL. included 43 SCD, 41 MCI 21 AD-demented (AD-d) patients, who underwent analysis. Twenty-eight AD-d CSF biomarkers analysis (Aβ1-42, Aβ1-42/1–40, p-tau, t-tau) were classified as carriers AD (AP+) it they A+/T+ , or non-carriers (AP−) when A−, A+/T−/N−, A+/T−/N+ according A/T(N) system. Plasma showed good (AUC = 0.88), while combined model (NfL + p-tau181) an excellent 0.92) AP+ AP− patients. moderately concordant (Coehn’s k 0.50, p < 0.001). Based on logistic regression model, we estimated risk considering two biomarkers: 10.91% if both negative; 41.10 76.49% only one biomarker was positive (respectively p-tau18 NfL); 94.88% positive. Considering moderate concordance presenting underlying positivity NfL, proposed flow chart guide use detect pathology.
Language: Английский
Citations
1
Current Alzheimer Research, Journal Year: 2023, Volume and Issue: 20(10), P. 715 - 724
Published: Oct. 1, 2023
Recent evidence suggests that blood-based biomarkers might be useful for Alzheimer's disease (AD). Among them, we intend to investigate whether neurofilament light (NfL) and multimer detection system-oligomeric Aβ (MDS-OAβ) values can in screening, predicting, monitoring progression how the relationship between NfL MDS-OAβ changes.
Language: Английский
Citations
3